Clinical Trials Logo

Prostatic Neoplasms clinical trials

View clinical trials related to Prostatic Neoplasms.

Filter by:

NCT ID: NCT00195039 Completed - Prostate Cancer Clinical Trials

Treatment With Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Metastatic Prostate Cancer

Start date: August 2004
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find out how effective 177Lu -J591 is in the treatment of patients with metastatic, androgen-independent prostate cancer.

NCT ID: NCT00193856 Completed - Prostate Cancer Clinical Trials

RADAR Trial - Randomised Androgen Deprivation and Radiotherapy

Start date: October 2003
Phase: Phase 3
Study type: Interventional

The principal objectives of the RADAR trial is to address the hypotheses; 1) that 18 months androgen deprivation in conjunction with radiotherapy is superior to 6 months androgen deprivation prior to and during radiotherapy; 2) that 18 months Bisphosphonate therapy will prevent bone loss caused by androgen deprivation therapy and further reduce relapse risk by impeding the development of bony metastases.

NCT ID: NCT00193271 Completed - Prostate Cancer Clinical Trials

Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer

Start date: August 2004
Phase: Phase 2
Study type: Interventional

This trial will evaluate the feasibility, toxicity, and efficacy of docetaxel/estramustine, as in the adjuvant therapy of patients with high-risk prostate cancer after definitive local therapy.

NCT ID: NCT00193232 Completed - Prostate Cancer Clinical Trials

Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

Start date: May 2004
Phase: Phase 2
Study type: Interventional

Evaluation of the effectiveness of weekly docetaxel/bortezomib as first-line chemotherapy for patients with advanced hormone-refractory prostate cancer.

NCT ID: NCT00193193 Completed - Prostate Cancer Clinical Trials

Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma

Start date: August 2000
Phase: Phase 2
Study type: Interventional

In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone refractory prostate cancer.

NCT ID: NCT00188799 Completed - Prostatic Neoplasms Clinical Trials

Xray Volume Imaging (Cone Beam CT) - Prostate Cancer

Start date: November 2003
Phase: Phase 2
Study type: Interventional

Conformal dose escalated radiotherapy was adopted as the standard treatment technique at PMH for intermediate risk patients with localised disease in 1997. This technique provides a much smaller margin of error for treatment set-up and delivery than with conventional techniques. One way to ensure the accuracy of treatment delivery is to image the prostate position daily, prior to therapy, to allow for appropriate set-up corrections. To do so, imaging markers are implanted into the prostate under guided ultrasound (a standard procedure at PMH). However, there are disadvantages in using imaging markers which include added time to the treatment planning process, and an invasive procedure with a potential for discomfort, bleeding and infection. This study will investigate and compare X-ray volume imaging to the gold standard imaging markers.

NCT ID: NCT00188786 Completed - Prostatic Neoplasms Clinical Trials

Cone Beam CT for Daily Image Guidance - Prostate Cancer

Start date: April 2005
Phase: Phase 2
Study type: Interventional

Conformal dose escalated radiation therapy (CRT) is standard treatment for patients with low and intermediate risk prostate cancer. CRT requires accurate daily localization of the prostate prior to treatment to correct for prostate motion and set-up errors. Cone beam computed tomography (CT) can accurately localize fiducial markers within the prostate. Cone Beam CT also provides important information on daily position of organs within the pelvis. This study aims to assess the feasibility of cone beam CT for daily localization of the prostate as well as document changes in size and location of pelvic organs during an entire course of CRT.

NCT ID: NCT00188708 Completed - Prostatic Neoplasms Clinical Trials

Effect of Casodex on Tumour Hypoxia - Prostate Cancer

Start date: April 2001
Phase: N/A
Study type: Interventional

Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.

NCT ID: NCT00188695 Completed - Prostatic Neoplasms Clinical Trials

Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide

Start date: April 2004
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to test whether or not a new contrast agent called Combidex, a contrast agent formulated from ultra-small superparamagnetic iron oxide (USPIO) improves the ability of Magnetic Resonance Imaging (MRI) to see lymph nodes in the pelvis. It might also help doctors tell whether or not cancer has spread to these lymph nodes. It might allow radiotherapy to be delivered more accurately.

NCT ID: NCT00188513 Completed - Prostatic Neoplasms Clinical Trials

Intensity Modulated Radiation Therapy - Prostate Cancer

Start date: May 2001
Phase: Phase 1/Phase 2
Study type: Interventional

There are several different treatment schedules being used across the world for treatment of prostate cancer with radiation therapy. In order to determine the best radiation treatment for this disease, a study is being performed by the doctors at the Princess Margaret Hospital. This study will try to measure the effectiveness and side effects of an increased dose of radiation to the prostate that is also given over a shorter number of weeks than is usually done. In order to try to reduce the possible side effects of the radiation therapy the treatment will be given using special techniques to shield as much of your normal body tissues as possible. This method of treatment is called conformal intensity modulated radiation therapy, or IMRT.